Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

909 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study.
Igarashi T, Kobayashi Y, Ogura M, Kinoshita T, Ohtsu T, Sasaki Y, Morishima Y, Murate T, Kasai M, Uike N, Taniwaki M, Kano Y, Ohnishi K, Matsuno Y, Nakamura S, Mori S, Ohashi Y, Tobinai K; IDEC-C2B8 Study Group in Japan. Igarashi T, et al. Among authors: morishima y. Ann Oncol. 2002 Jun;13(6):928-43. doi: 10.1093/annonc/mdf155. Ann Oncol. 2002. PMID: 12123339 Free article. Clinical Trial.
Re-treatment of relapsed indolent B-cell lymphoma with rituximab.
Igarashi T, Ohtsu T, Fujii H, Sasaki Y, Morishima Y, Ogura M, Kagami Y, Kinoshita T, Kasai M, Kiyama Y, Kobayashi Y, Tobinai K; IDEC-C2B8 Study Group. Igarashi T, et al. Among authors: morishima y. Int J Hematol. 2001 Feb;73(2):213-21. doi: 10.1007/BF02981940. Int J Hematol. 2001. PMID: 11372734 Clinical Trial.
Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505.
Itoh K, Ohtsu T, Fukuda H, Sasaki Y, Ogura M, Morishima Y, Chou T, Aikawa K, Uike N, Mizorogi F, Ohno T, Ikeda S, Sai T, Taniwaki M, Kawano F, Niimi M, Hotta T, Shimoyama M, Tobinai K; Members of the lymphoma study group of the Japan Clinical Oncology Group (JCOG). Itoh K, et al. Among authors: morishima y. Ann Oncol. 2002 Sep;13(9):1347-55. doi: 10.1093/annonc/mdf287. Ann Oncol. 2002. PMID: 12196359 Free article. Clinical Trial.
Phase III trial of CHOP-21 versus CHOP-14 for aggressive non-Hodgkin's lymphoma: final results of the Japan Clinical Oncology Group Study, JCOG 9809.
Ohmachi K, Tobinai K, Kobayashi Y, Itoh K, Nakata M, Shibata T, Morishima Y, Ogura M, Suzuki T, Ueda R, Aikawa K, Nakamura S, Fukuda H, Shimoyama M, Hotta T; members of the Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG-LSG). Ohmachi K, et al. Among authors: morishima y. Ann Oncol. 2011 Jun;22(6):1382-1391. doi: 10.1093/annonc/mdq619. Epub 2010 Dec 31. Ann Oncol. 2011. PMID: 21196441 Free article. Clinical Trial.
A dose-finding study of lenograstim (glycosylated rHuG-CSF) for peripheral blood stem cell mobilization during postoperative adjuvant chemotherapy in patients with breast cancer. Lenograstim/Breast Cancer Study Group.
Narabayashi M, Takeyama K, Fukutomi T, Tokuda Y, Tajima T, Okumura A, Chou T, Sano M, Makino H, Igarashi T, Sasaki Y, Imoto S, Ogura M, Morishima Y, Murai H, Okamoto S, Ikeda T, Kasai M, Yokozawa T, Tobinai K. Narabayashi M, et al. Among authors: morishima y. Jpn J Clin Oncol. 1999 Jun;29(6):285-90. doi: 10.1093/jjco/29.6.285. Jpn J Clin Oncol. 1999. PMID: 10418556 Clinical Trial.
Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma.
Yatabe Y, Suzuki R, Tobinai K, Matsuno Y, Ichinohasama R, Okamoto M, Yamaguchi M, Tamaru J, Uike N, Hashimoto Y, Morishima Y, Suchi T, Seto M, Nakamura S. Yatabe Y, et al. Among authors: morishima y. Blood. 2000 Apr 1;95(7):2253-61. Blood. 2000. PMID: 10733493 Free article.
Randomized comparison of mobilization kinetics of circulating CD34+ cells between biweekly CHOP and dose-escalated CHOP with the prophylactic use of lenograstim (glycosylated rHuG-CSF) in aggressive non-Hodgkin's lymphoma. The lenograstim/Lymphoma Study Group.
Itoh K, Ohtsu T, Sasaki Y, Ogura M, Morishima Y, Kasai M, Chou T, Yoshida K, Ohno T, Mizorogi F, Uike N, Sai T, Taniwaki M, Ikeda S, Tobinai K. Itoh K, et al. Among authors: morishima y. Leuk Lymphoma. 2000 Aug;38(5-6):521-32. doi: 10.3109/10428190009059271. Leuk Lymphoma. 2000. PMID: 10953973 Clinical Trial.
909 results